Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Versatis 700 mg medicated plaster

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 10 cm x 14 cm plaster contains 700 mg lidocaine (equivalent to 5% w/w)

Excipient(s) with known effect: Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Propylene glycol (E1520)

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Medicated plaster

Product imported from France and Italy:

White hydrogel plaster containing adhesive material, which is applied to a non-woven polyethylene terephthalate backing embossed with "Lidocaine 5%" and covered with a polyethylene terephthalate film release liner.

4 CLINICAL PARTICULARS

As per PA2242/007/001

5 PHARMACOLOGICAL PROPERTIES

As per PA2242/007/001

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Self-adhesive layer:

glycerol liquid sorbitol carmellose sodium propylene glycol (E1520) urea

heavy kaolin

tartaric acid

gelatin

polyvinyl alcohol

aluminium glycinate

disodium edetate

methyl parahydroxybenzoate (E218)

propyl parahydroxybenzoate (E216)

polyacrylic acid

sodium polyacrylate

purified water

Backing fabric:

Polyethylene terephthalate (PET)

08 March 2024 CRN00F565 Page 1 of 2

Release liner:

Polyethylene terephthalate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

The shelf-life expiry of the unopened product is the date shown on the sachet and outer package of the product as marketed in the country of origin.

After first opening the sachet, the plasters must be used within 14 days.

6.4 Special precautions for storage

Do not refrigerate or freeze.

After first opening: Keep the sachet tightly closed to protect from light.

6.5 Nature and contents of container

Re-sealable sachet composed of paper/polyethylene/aluminium/ethylene meta-acrylic acid co-polymer containing 5 plasters. Each carton contains 10 or 30 plasters.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

After use the plaster still contains active substance. After removal, the used plasters should be folded in half, adhesive side inwards so that the self-adhesive layer is not exposed, and the plaster should be discarded.

Any unused product or waste material should be disposed of in accordance with local requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

Merit Pharmaceuticals Limited Unit C4/C3 Metropoint Business Park Kettles Lane Swords Co Dublin K67 RH92 Ireland

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA23080/013/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 4th July 2014

10 DATE OF REVISION OF THE TEXT

March 2024

08 March 2024 CRN00F565 Page 2 of 2